Do you want to read an article? Please log in or register.
Initiation of triple therapy maintenance treatment among patients with COPD in the US.
Related content
COMMENTED
Long-term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in COPD Patients (SUNSET): a Randomized, Double-Blind, Triple-Dummy Clinical Trial
Am J Respir Crit Care Med.
Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA
doi: 10.1164/
Asthma
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
Eur Respir J.
Jorup C, Lythgoe D, Bisgaard H
doi: 10.1183/
COMMENTED
COPD
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Lancet Respir Med.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C
doi: 10.1016/S2213-2600
AsthmaCOPD
Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey
Int J Chron Obstruct Pulmon Dis
Ding B, Small M
doi: 10.2147/COPD.S136314.
RECOMMENDED
COPD
Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study
Lancet Respir Med.
Suissa S, Dell'Aniello S, Ernst P
doi: 10.1016/S2213-
RECOMMENDED
COPD
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D
doi: 10.1186/s12931-020-01360-w.
RECOMMENDED
COPD
Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups
Respir Med.
Bakerly ND, Woodcock A,
Collier S, Leather DA, New JP,
Crawford J, Harvey C, Vestbo J,
Boucot I
doi: 10.1016/j.rmed.2018.12.016.
RECOMMENDED
COPD
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA
doi: 10.1186/s12931-020-01398-w.
RECOMMENDED
COPD
Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations
Respir Med.
Djamin RS, Bafadhel M, Uzun S, Russell REK, Ermens AAM, Kerstens R, Aerts JGJV, Pavord ID, van der Eerden MM
doi: 10.1016/j.rmed.2019.06.005.